Entry for Emerging Strategic Opportunities Code: PAB Name:...

Entry for Emerging Strategic Opportunities

Code: PAB
Name: Patrys Ltd
Sector: Pharmaceuticals, Biotechnology and Life Sciences
Total Shares Listed : 696, 760,986
Unlisted: 22,135,559

Previous close $0.033
52 Week High $0.092
52 Week Low $0.024
Market Cap $25 Million


Fundamental Analysis

Patrys is a publicly-listed company on the Australian Securities Exchange (ASXAB). The Company's headquarters are in Melbourne, Australia, and main R&D center is in Würzburg, Germany, where the technology platform and product pipeline was first developed.

The principal focus is on the development of a completely new type of product for the treatment of cancer – natural human antibodies. These natural human antibodies potentially offer the promise of increased potency coupled with greater safety as compared to existing cancer treatments.

In March 2014 Patrys completed a Phase I/IIa clinical trial in multiple myeloma for PAT-SM6. The primary endpoint of the study was safety and tolerability. At all dose levels PAT-SM6 was well tolerated with no serious adverse events of dose limiting toxicities.
Overall, 4/12 patients (33%) treated with PAT-SM6 showed evidence of stable disease according to the International Myeloma Working Group (IMWG) criteria. One patient who received 3mg/kg of PAT-SM6 was stable for 138 days before additional therapy was needed whilst another patient, who receivd 6mg/kg of PAT-SM6, has been stable for 154 days and is currently therapy free. Importantly, patients treated with PAT-SM6 had a mean time to next therapy of 51 days which is considered clinically significant. Patrys is currently preparing for the next clinical trial in which PAT-SM6 will be tested in combination with Amgen's Carfilzomib.

In addition to PAT-SC1 and PAT-SM6, Patrys has a deep pipeline of other promising products, which Patrys can use to refill its pipeline. These include PAT-LM1, which has a strong preclinical profile, and which Patrys is looking to move to the clinical setting.
This deep pipeline, when coupled with a first-move position in the natural human antibody space, presents the Company with a diverse number of value drivers going forward.

Compared to existing cancer treatments, Patrys’ natural human antibodies offer differentiating and potentially valuable product features, including:

• • 100% human composition, reducing the risk of immune rejection and potentially offering greater potency.
• • Attacking cancer cells while leaving healthy tissue unharmed, in turn offering a safer treatment profile.
• • Killing cancer cells via different mechanisms to currently marketed and largely ineffective treatments
• (i.e., each Patrys antibody binds to a newly discovered and proprietary disease target).
• • Being potentially effective across the spectrum of patients, regardless of age, gender or stage of disease.
• • Being applicable to many different deadly cancers, including melanoma, gastric cancer, multiple myeloma and pancreatic

World Class Management and major backers with a proven track record.